Sign In
Buy MBRX
$2.46
+0 (+0%)
At Close: Jun 03, 2026
Moleculin to Present at 38th Annual ROTH Conference
09:05am, Tuesday, 17'th Mar 2026
– Management to participate in fireside chat presentation with Jonathan Aschoff, Senior Research Analyst at ROTH Capital Partners
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
09:00am, Wednesday, 11'th Mar 2026
Access the Moleculin CEO Corner here
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
08:39am, Thursday, 19'th Feb 2026
HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its ex
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
08:20am, Wednesday, 18'th Feb 2026
Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failures First 45 subjects treated on tra
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
08:35am, Tuesday, 17'th Feb 2026
HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of all
Moleculin Biotech Highlights Phase 3 Annamycin AML Catalysts, Eyes Partnering Within 12 Months
01:02am, Monday, 16'th Feb 2026
Moleculin Biotech (NASDAQ: MBRX) CEO and Chairman Walter Klemp outlined the company's near-term priorities and upcoming clinical catalysts during a corporate presentation, emphasizing progress in its
Moleculin Launches CEO Corner Platform to Share Strategic Insights
08:32am, Friday, 13'th Feb 2026
CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company
Moleculin Biotech (NASDAQ:MBRX) Stock Crosses Below Fifty Day Moving Average – Time to Sell?
04:38am, Saturday, 07'th Feb 2026
Moleculin Biotech, Inc. (NASDAQ: MBRX - Get Free Report) shares passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $4.58 and traded as low
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
09:15am, Thursday, 05'th Feb 2026
– Live video webcast on Wednesday, February 11 th at 1:20 PM EST
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
08:55am, Tuesday, 13'th Jan 2026
– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating mu
– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWS
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta Results demonstrated WP1066 induces anti-tumor immune r
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
08:30am, Wednesday, 10'th Dec 2025
HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
08:07am, Tuesday, 09'th Dec 2025
Continues to drive enrollment with increase to 78% now consented Blinded response activity tracking within expected range
Moleculin Announces New Annamycin Collaboration in Brain Tumors
08:21am, Monday, 08'th Dec 2025
Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec. 08, 2025
